Login

274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency

Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
DOI: 10.1136/jitc-2023-sitc2023.0274 Publication Date: 2023-10-31T13:48:37Z
Abstract Supplemental Material References Cited by
AUTHORS (41)
Demetrios Kalaitz...
Mohammed Ghonime
Robert Chain
Nivedita Jaishankar
Davis Settipane
Zinkal Padalia
Lauren Zakas
Meghna Kuppuraju
Paul Tetteh
Mary-Lee Dequeant
Sushant Karnik
Chandirasegaran M...
Brigid McEwan
Henia Dar
Melanie Allen
Laura Serwer
Thao Nguyen
Melanie Butler-Ga...
Parin Sripakdeevong
Shashwat Nagar
Yin Tang
Nicole Flanagan
Elaine Huang
Shashwant Phuyal
Andrew Dunn
Elizabeth Koch
Erisa Sula
Jacob Waldman
Maria Lei Zhang
Cristian Loaiza
Erin Thorstensen
Keith Steiger
Katie Schum
Kayla Urbaez
Anna Ma
Annie Yang Weaver
Christopher Finch
Sarah Cohen
PK Morrow
Mark Benton
Jonathan Terrett
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
OPENAIRE - Products  CROSSREF - Publications 
PlumX Metrics
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency 
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....

Powered by

  • AIX SEMS NFDI4DS

Legal

  • Impressum Datenschutz

Connect